IONS Earnings Prediction
The chart below shows how IONS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IONS sees a +2.59% change in stock price 10 days leading up to the earnings, and a -1.25% change 10 days following the report. On the earnings day itself, the stock moves by -0.80%. This data can give you a slight idea of what to expect for the next quarter's release.
IONS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
133.81M
-7.21%
-40.59%
Gross Margin
99.20%
0.73%
1.07%
Operating Margin
-111.09%
11.82%
278.63%
Net Margin
-104.98%
2.70%
256.83%
EPS
-0.95
-7.77%
111.11%
No Data Available
IONS Earnings Analysis
Ionis Pharmaceuticals, Inc. Common Stock Corporation (IONS.O) Earnings Conference Call
Positive
Product Launch Strategy: 1. Upcoming Product Launches: Ionis is preparing for its first independent launch of Olezarsen for familial chylomicronemia syndrome (FCS) on December 19, 2024, with three additional independent launches anticipated over the next three years.
Strong Revenue Surge: 2. Strong Revenue Growth from WAINUA: WAINUA product sales increased by 44% in Q3 2024 compared to Q2 2024, reflecting strong demand and patient growth from new and switching patients.
Acute Pancreatitis Reduction: 3. Significant Reduction in Acute Pancreatitis Events: In the Phase 3 Balance study for Olezarsen, patients experienced a 90% mean reduction in acute pancreatitis events compared to the placebo group, with only one event in the treatment group after nearly a year of treatment.
Donidalorsen Trial Success: 4. High Efficacy in Donidalorsen Trials: Donidalorsen demonstrated a sustained mean reduction in hereditary angioedema (HAE) attack rates of over 90% with one year of treatment, indicating its potential as a preferred prophylactic treatment.
Pipeline Advancements and Readouts: 5. Robust Pipeline Advancements: Ionis has eight positive data readouts from its mid and late-stage pipeline this year, with six Phase 3 studies completed, positioning the company for significant value-driving events in the near future.
Negative
Revenue Decline Analysis: 1. Declining Revenue: Ionis reported a 7% decrease in revenues for Q3 2024 compared to the same period last year, totaling $134 million, indicating potential challenges in maintaining sales momentum.
Rising Operating Expenses: 2. Increased Operating Expenses: The company's SG&A expenses rose by 13% in Q3 2024 compared to the previous year, driven by higher sales and marketing costs, which could impact profitability.
Stagnant R&D Investment: 3. Flat R&D Expenses: Research and development expenses remained essentially flat year-over-year, suggesting potential limitations in advancing new projects or innovations in the pipeline.
Equity Offering for Stability: 4. Equity Offering for Cash Runway: Ionis executed an equity offering to extend its cash runway, indicating concerns about financial stability and the need for additional funding to support operations and growth.
Study Data Readout Delay: 5. Delayed Data Readouts: The timeline for the CARDIO-TTRansform study data readout has shifted to the second half of 2026, which may hinder the company's ability to capitalize on market opportunities in a timely manner.
IONS FAQs
How does IONS typically perform around its earnings report dates?
Is Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IONS Earning Call Sentiment
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
IONS.O
-2.82%Positive
The earnings call reveals mixed signals. Financial performance shows a revenue decline due to a one-time event, but there's growth in other areas. Expenses are rising, but cash position is strong. Q&A highlights potential in new launches but lacks clarity in some responses. Overall, the sentiment is balanced, with positive developments like WAINUA's growth offset by concerns over expenses and vague management responses.
